(390 days)
K971509: ENDOXANE
No
The description mentions "automatically calculate a centerline" and "segment the airway," which are image processing tasks. However, it does not explicitly state that AI or ML algorithms are used for these tasks. The design process is described as physician-driven using the software as a tool, not as an AI/ML-driven design process. There is no mention of AI, DNN, or ML in the provided text, nor are there descriptions of training or test sets typically associated with AI/ML models.
Yes.
The device is a silicone stent intended for implantation in the airway to treat symptomatic stenosis, which directly addresses a medical condition.
No
The device is a stent used for treatment (implantation to relieve symptomatic stenosis), not for diagnosing a condition. While it uses CT scans for design, it does not interpret or analyze the scans to determine a diagnosis.
No
The device description explicitly states that the system is comprised of "Web Software and the Patient-Specific Silicone Y-Stent," and that "These two function together as a system." The performance studies also include extensive testing on the physical stent component (Sterilization, Tear Strength, Radial Compression, Fatigue, Biocompatibility, etc.), indicating it is a hardware device with accompanying software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended to be used in vitro for the examination of specimens, including blood, tissue, and urine, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential recipients, or to monitor therapeutic measures.
- Device Function: This device is a Patient-Specific Airway Stent intended for implantation into the airway to treat symptomatic stenosis. It is a physical implant designed to mechanically open a narrowed airway.
- Intended Use: The intended use is for the treatment of a medical condition (airway stenosis) by providing a physical support structure within the body.
- Specimen Examination: The device does not involve the examination of specimens derived from the human body in vitro. While it uses a CT scan (an imaging modality) to guide the design, the device itself does not analyze biological samples.
The device is a medical device that utilizes software for design based on imaging data, but its primary function and intended use are not related to in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The Patient-Specific Airway Stent is indicated for the treatment of adults ≥22 years of age with symptomatic stenosis of the airway. The silicone stent is intended for implantation into the airway by a physician using the recommended deployment system or an equivalent rigid bronchoscope and stent placement system that accepts the maximum stent diameter being placed. The stent is intended to be in the patient up to 12 months after initial placement.
Product codes
NWA
Device Description
The Patient-Specific Airway Stent is comprised of Web Software and the Patient-Specific Silicone Y-Stent. These two function together as a system to treat symptomatic stenosis of the airway. The Patient-Specific Silicone Stent is designed by a physician using a CT scan as a guide in the Web Software. The Web Software gives the user (physician) the ability to upload a scan, view the airway, and design a stent. The stent, after physician approval, is manufactured via silicone injection into a 3D-printed mold and delivered to the treating physician's medical center nonsterile.
The Patient-Specific Airway Stent includes the following general features:
- Deployed through a common applicator system in conjunction with an . appropriate rigid bronchoscope system
- Made of biocompatible, implant-grade silicone
- Steam sterilizable ●
- Anti-Migration studs on anterior surface ●
- Single-use only .
- Branched (Y-Stent) to prevent migration .
- Designed and approved in a proprietary software by a physician for an individual . patient
The Web Software has the following general features:
- Gives COS technicians the ability to segment the airway and automatically ● calculate a centerline
- Create, edit, and save patient-specific airway stents from segmented airway ●
- . Define exact stent diameters at specific locales
- Measure stent inner and outer diameters at any point along stent design .
- . CT scan as the imaging input modality
- Physician able to manage patient's stent designs and CT scans ●
- Physician able to approve stent design through software (create 3D prescription) .
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT scan
Anatomical Site
airway
Indicated Patient Age Range
adults ≥22 years of age
Intended User / Care Setting
Physician, medical center
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
- Sterilization Testing: Confirms that the subject device can be steam sterilized to a SAL of 10-6, using a common cycle in medical centers.
- Tear Strength Testing: Supports the claim that the subject device's material is equivalent to the predicate's material in tear strength.
- Radial Compression Testing: Compares the compression strength of the subject device against the predicate device.
- Fatigue Testing: Supports the claim that the subject device does not fatigue when cyclically compressed over the intended life of the implant (1 year).
- Stent Deployment Testing: Supports the claim that the subject device is able to be deployed by a common applicator and rigid bronchoscope system.
- Biocompatibility Testing: Supports the claim that the subject device is acceptable to implant in terms of biocompatibility for up to one year; identical to the predicate device's permanent implantation duration. Tests include: Cytotoxicity (MEM Elution Test), Sensitization (Guinea Pig Maximization Test), Irritation (Intracutaneous Reactivity), Toxicity (Acute Systemic Toxicity), Pyrogenicity (Material-Mediated Pyrogenicity), Subacute/Sub-Chronic Toxicity (Sub-Chronic Intramuscular Implantation in Rabbits for 90days with Histopathology), Genotoxicity (Ames Bacterial Reverse Mutation Assay), Genotoxicity (Mouse Lymphoma Assay), Genotoxicity (In Vivo Mouse Micronucleus Mutagenicity Assay), Chemical Characterization of Extractables and Leachables.
- Software Verification and Validation Testing: Supports the claim that the software functions as designed, including any design mitigations included to reduce risks associated with the addition of software and patient-specific stent creation into the subject device. Software classified as a Major level of concern.
- Human Factors and Usability Testing for Web Software: Supports the claim that the software is as safe and as effective as the predicate device when used by its intended users in its intended use-environment.
- Migration Testing: Bench testing in procedural training model to test migration forces required to dislodge an implanted patient-specific airway stent.
- Accelerated Aging Testing: Testing to evaluate the shelf-life of the patient-specific airway stents.
- Dimensional Testing of Airway Segmentation: Evaluated the accuracy of segmented airway rendering in proprietary segmentation software.
- Airway Segmentation Process Validation: Validated the process of segmenting an airway from a CT scan in proprietary segmentation software.
Key Metrics
Not Found
Predicate Device(s)
K971509: ENDOXANE
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.3720 Tracheal prosthesis.
(a)
Identification. The tracheal prosthesis is a rigid, flexible, or expandable tubular device made of a silicone, metal, or polymeric material that is intended to be implanted to restore the structure and/or function of the trachea or trachealbronchial tree. It may be unbranched or contain one or two branches. The metal tracheal prosthesis may be uncovered or covered with a polymeric material. This device may also include a device delivery system.(b)
Classification. Class II. The special control for this device is FDA's “Guidance for the Content of Premarket Notification Submissions for Esophageal and Tracheal Prostheses.”
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 23, 2019
New COS Inc. Keith Grafmeyer Sr. Project Manager 7100 Euclid Ave, Ste 180 Cleveland, Ohio 44103
Re: K182743
Trade/Device Name: Patient-Specific Airway Stent Regulation Number: 21 CFR 878.3720 Regulation Name: Tracheal Prosthesis Regulatory Class: Class II Product Code: NWA Dated: October 17, 2019 Received: October 18, 2019
Dear Keith Grafmeyer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
James J. Lee, Ph.D. Assistant Director DHT1C: Division of ENT, Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K182743
Device Name Patient-Specific Airway Stent
Indications for Use (Describe)
The Patient-Specific Airway Stent is indicated for the treatment of adults ≥22 years of age with symptomatic stenosis of the airway. The silicone stent is intended for implantation into the airway by a physician using the recommended deployment system or an equivalent rigid bronchoscope and stent placement system that accepts the maximum stent diameter being placed. The stent is intended to be in the patient up to 12 months after initial placement.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------ | ----------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
510(k) OWNER / MANUFACTURER: New COS, Inc. 7100 Euclid Ave Ste 180 Cleveland OH, 44103
| CONTACT PERSON: | Keith Grafmeyer
Sr. Product Manager
New COS, Inc.
Tel: (216) 800-5905 x 102
Email: kgrafmeyer@customorthopaedics.com |
| ----------------- | ---------------------------------------------------------------------------------------------------------------------------------- |
|---|
TRADE NAMES: Patient-Specific Airway Stent
October 23, 2019 PREPARATION DATE:
COMMON NAMES: Prosthesis, Tracheal, Preformed/Molded
| Product: Patient-Specific | Product
Code | Regulation and Classification
Name | Device
Class |
|--------------------------------------|-----------------|----------------------------------------|-----------------|
| Patient-Specific Airway Stent System | NWA | 21 CFR 878.3720
Tracheal Prosthesis | II |
PREDICATE DEVICE:
| Subject Device: Patient-Specific Airway
| Stent | Corresponding Predicate Device(s) |
|---|---|
| Patient-Specific Airway Stent | K971509: ENDOXANE |
REFERENCE DEVICES:
| Device 510(k) Number | Device Name | Reason for Use |
|---|---|---|
| K073468 | Mimics | Performance |
| specification for airway | ||
| segmentation | ||
| K894380 | Dumon Tracheobronchial Stent | Performance |
| specification for | ||
| compression strength | ||
| K121048 | Ultraflex Tracheobronchial Stent | |
| System – Sterile Uncovered | Performance | |
| specification for | ||
| compression strength |
DEVICE DESCRIPTION:
The Patient-Specific Airway Stent is comprised of Web Software and the Patient-Specific Silicone Y-Stent. These two function together as a system to treat symptomatic stenosis of the airway. The Patient-Specific Silicone Stent is designed by a physician using a CT scan as a guide in the Web Software. The Web Software gives the user (physician) the ability to upload a scan, view the airway, and design a stent. The stent, after physician approval, is manufactured via silicone injection into a 3D-printed mold and delivered to the treating physician's medical center nonsterile.
4
The Patient-Specific Airway Stent includes the following general features:
- Deployed through a common applicator system in conjunction with an . appropriate rigid bronchoscope system
- Made of biocompatible, implant-grade silicone
- Steam sterilizable ●
- Anti-Migration studs on anterior surface ●
- Single-use only .
- Branched (Y-Stent) to prevent migration .
- Designed and approved in a proprietary software by a physician for an individual . patient
The Web Software has the following general features:
- Gives COS technicians the ability to segment the airway and automatically ● calculate a centerline
- Create, edit, and save patient-specific airway stents from segmented airway ●
- . Define exact stent diameters at specific locales
- Measure stent inner and outer diameters at any point along stent design .
- . CT scan as the imaging input modality
- Physician able to manage patient's stent designs and CT scans ●
- Physician able to approve stent design through software (create 3D prescription) .
INTENDED USE AND INDICATIONS:
The Patient-Specific Airway Stent is indicated for the treatment of adults ≥22 years of age with symptomatic stenosis of the airway. The silicone stent is intended for implantation into the airway by a physician using the recommended deployment system or an equivalent rigid bronchoscope and stent placement system that accepts the maximum stent diameter being placed. The stent is intended to be in the patient up to 12 months after initial placement.
BASIS OF SUBSTANTIAL EQUIVALENCE:
The Patient-Specific Airway Stent is substantially equivalent to the ENDOXANE stent (K971509) with regards to intended use and indications for use.
The materials used to design the Patient-Specific stent are substantially equivalent to the materials used to manufacture the Endoxane stents and the performance characteristics of the subject device have been tested to show substantial equivalency to the currently marketed predicate device. Biocompatibility testing has confirmed that the Patient-Specific Silicone Stent is acceptable for use as a medical device following the requirements stated in the FDA's Guidance on the Use of ISO 10993-1.
The primary technological difference between the subject and predicate device is the introduction of software to allow a physician to design a stent for a specific patient. The risks introduced by this difference have been mitigated in the software, rendering the subject device's risk profile substantially equivalent to the predicate. Software verification and validation was performed to confirm that the software fully satisfies all inputs.
5
TECHNOLOGICAL CHARACTERISTICS SUMMARY:
The Patient-Specific Airway Stent is substantially equivalent to the predicate device in terms of technological characteristics including design, materials, and features.
Identical Characteristics
- । Branched (Y) stent configurations (no more than 3 branches).
- Method of deployment through a common applicator system in coniunction with । an appropriate rigid bronchoscope system based on the maximum outer diameter being deployed.
- Uniform wall thickness option of 1.0mm.
- Visually smooth interior and exterior surfaces of device. |
- । Removable implant, if necessary (recommended to be replaced after 12 months of implantation).
- -Single-use implant only.
- Uniform material composed of biocompatible, implant-grade silicone proven | through performance and biocompatibility testing according to ISO 10993-1.
- Sterilizable silicone material via common steam cycle from AAMI ST79. -
- -Anti-migration studs on anterior surface of main branch of stent.
Technological Differences
- (Subject) Stent is designed by a Physician using software for a specific patient vs. (Predicate) Stent is chosen from stock designs out of a catalog for a specific patient.
- (Subiect) Ability to vary the inner diameter of the stent at any location along the । stent from 6mm-18mm in 0.1mm increments (patient-specific design with software) vs. (Predicate) Discretely vary the inner diameter from 8-18mm in 1.0mm increments (stock stent design from catalog)
- (Subject) Ability to vary the length of the stent up to 145mm according to the । patient's anatomy vs. (Predicate) Ability to vary length up to 110mm based on available stent designs in a catalog
- (Subject) 3D-printed molds for silicone injection vs (Predicate) Machined molds । for silicone iniection
- (Subject) Secondary branch angle ≤ 100° vs (Predicate) Secondary branch | angle always 75°
- Subject device has lower flat-plate compression strength than the predicate | device
Any risks related to these technological differences have been mitigated to an acceptable level, rendering the subject device substantially equivalent to the predicate device. The technological characteristics, including all design mitigations, have been verified and validated.
NON-CLINCICAL PERFORMANCE TESTING
Performance and functional testing were performed to ensure the Patient-Specific Airway Stent functions according to the inputs and demonstrates substantial equivalence to the predicate device.
- Sterilization Testing Confirms that the subject device can be steam sterilized to a SAL of 10-6, using a common cycle in medical centers.
- Tear Strength Testing - Supports the claim that the subject device's material is equivalent to the predicate's material in tear strength.
6
- Radial Compression Testing Compares the compression strength of the | subject device against the predicate device
- -Fatique Testing - Supports the claim that the subject device does not fatigue when cyclically compressed over the intended life of the implant (1 year)
- । Stent Deployment Testing – Supports the claim that the subject device is able to be deployed by a common applicator and rigid bronchoscope system
- । Biocompatibility Testing - Supports the claim that the subject device is acceptable to implant in terms of biocompatibility for up to one year; identical to the predicate device's permanent implantation duration.
- Cytotoxicity: MEM Elution Test с
- o Sensitization: Guinea Pig Maximization Test
- Irritation: Intracutaneous Reactivity O
- Toxicity: Acute Systemic Toxicity O
- Pyrogenicity: Material-Mediated Pyrogenicity O
- Subacute/Sub-Chronic Toxicity: Sub-Chronic Intramuscular Implantation o in Rabbits for 90days with Histopathology
- O Genotoxicity: Ames Bacterial Reverse Mutation Assay
- Genotoxicity: Mouse Lymphoma Assay o
- Genotoxicity: In Vivo Mouse Micronucleus Mutagenicity Assay O
- Chemical Characterization of Extractables and Leachables o
- Software Verification and Validation Testing Supports the claim that the । software functions as designed, including any design mitigations included to reduce risks associated with the addition of software and patient-specific stent creation into the subject device. Per FDA's Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, the software was classified as a Major level of concern.
- । Human Factors and Usability Testing for Web Software – Supports the claim that the software is as safe and as effective as the predicate device when used by its intended users in its intended use-environment.
- -Migration Testing - Bench testing in procedural training model to test migration forces required to dislodge an implanted patient-specific airway stent
- Accelerated Aging Testing Testing to evaluate the shelf-life of the patient- specific airway stents
- । Dimensional Testing of Airway Segmentation - Evaluated the accuracy of segmented airway rendering in proprietary segmentation software
- -Airway Segmentation Process Validation - Validated the process of segmenting an airway from a CT scan in proprietary segmentation software
CONCLUSION
The Patient-Specific Airway Stent is substantially equivalent to the predicate device in intended use, indications for use, principle of operation, and technological characteristics.